Abstract
Introduction: Coronary heart disease (CHD) is a cardiovascular disease with a high incidence in elderly patients. This article aimed to evaluate the clinical efficacy of puerarin (Pue) as an adjuvant therapy in elderly patients with CHD, and the effects of Pue on serum NOD-like receptor protein 3 (NLRP3) inflammasome, C1q/TNF-Related Protein 3 (CTRP3) and lipoprotein-associated phospholipase 2 (Lp-PLA2) levels.
Method: A total of 118 elderly patients with CHD admitted to Beijing University of Chinese Medicine Third Affiliated HospitaL and 24 induced CHD rat models were enrolled. The controls received conventional treatment, and the study subjects received 5% glucose injection 500mL+Pue injection 0.4g, intravenous drip once a day, 7 days as a course of treatment based on conventional treatment. The improvement of clinical symptoms in patients with CHD and the changes of serum NLRP3 inflammasome, CTRP3 and Lp-PLA2 levels in patients and experimental rats were compared.
Result: Relative to the controls, the study subjects had a reduction in the number of angina episodes and an increase in exercise tolerance. In addition, the serum NLRP3 inflammasome and Lp-PLA2 were distinctly decreased, and the serum CTRP3 was distinctly raised in study subjects and experimental rats. C
onclusion: Pue may improve the inflammatory state and lipid metabolism in patients with CHD by inhibiting NLRP3 inflammasome and regulating the levels of biomarkers such as CTRP3 and Lp-PLA2, thereby reducing symptoms and improving the quality of life.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.